Erratum to Two-Year Results of a Low-Dose Drug-Coated Balloon for Revascularization of the Femoropopliteal Artery: Outcomes From the ILLUMENATE First-in-Human Study (10.1002/ccd.25900);Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first-in-human study

Catheterization and Cardiovascular Interventions

Volumn 86, Issue 2, 2015, Pages 278-286

  Schroeder, Henrik ^a   Meyer, Dirk Roelfs ^b   Lux, Beata ^c   Ruecker, Ferdinand ^a   Martorana, Marcello ^a   Duda, Stephan ^a  

^a Jewish Hospital   (Germany)

^b St Hubertus Hospital   (Germany)

^c St Joseph Hospital   (Germany)

Author keywords

claudication; paclitaxel coated balloon; peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; MACROGOL; PACLITAXEL; TICLOPIDINE; BIOMATERIAL; CARDIOVASCULAR AGENT;

AGED; ARTERY DISEASE; ARTICLE; BALLOON CATHETER; BALLOON DILATATION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE SAFETY; DRUG COATED ANGIOPLASTY BALLOON; FEMALE; FEMOROPOPLITEAL ARTERY DISEASE; HEART DEATH; HUMAN; LEG AMPUTATION; LEG REVASCULARIZATION; LIMB ISCHEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPLITEAL ARTERY; PROSPECTIVE STUDY; RESTENOSIS; SUPERFICIAL FEMORAL ARTERY; TREATMENT OUTCOME; ADVERSE EFFECTS; CLINICAL TRIAL; DEVICES; DISEASE FREE SURVIVAL; FEMORAL ARTERY; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN; RADIOGRAPHY; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

AGED; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; DISEASE-FREE SURVIVAL; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84937399686     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26590     Document Type: Erratum

References (17)

1. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR III, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA,. Prevention of atherothrombotic disease N. Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med 2003; 163: 884-892.
2. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH,. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013; 382: 1329-1340.
3. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, Viva PI,. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007; 69: 910-919.
4. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, Minar E,. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: Propensity score-adjusted analysis. Radiology 2004; 232: 516-521.
5. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR,. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the resilient randomized trial. Circ Cardiovasc Interv 2010; 3: 267-276.
6. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS,., Zilver PTXI,. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month zilver ptx randomized study results. Circ Cardiovasc Interv 2011; 4: 495-504.
7. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T, Zilver PTXS- ASI. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: Twelve-month safety and effectiveness results from the zilver ptx single-arm clinical study. J Endovasc Ther 2011; 18: 613-623.
8. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A,. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315.
9. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J,. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation 2008; 118: 1358-1365.
10. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U,. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-699.
11. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K,. The LEVANT 1 (lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: First-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014; 7: 10-19.
12. Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G,. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: Evidence from a multicenter registry. JACC Cardiovasc Interv 2013; 6: 282-289.
13. Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G,. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter italian registry. JACC Cardiovasc Interv 2012; 5: 331-338.
14. Shammas NW, Shammas G, Bryan D, Rauba J, Dippel E, Jerin M,. Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions. J Invasive Cardiol 2009; 21: 266-269.
15. Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, Scheller B, Speck U,. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: An additional analysis from the thunder study. J Endovasc Ther 2013; 20: 792-800.
16. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR,. Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv 2014; 84: 546-554.
17. Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, d'Adamo A, Salvatori FM,. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014; 37: 898-907.